SUBSCRIBE
SUBSCRIBE
News   Drug Development

ImmuPharma plc’s Cancer Drug Candidate IPP- 204106 Shows Complete Response to Tumours in Multiple Human Cancer Cell Lines

May 21, 2008 | 
1 min read
LONDON, May 20, 2008-ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces today pre-clinical data on its new cancer drug, IPP-204106.
Preclinical Europe
MORE ON THIS TOPIC
A brain hovers over a hand against a yellow-striped background
Huntington’s disease
Roche scraps 2 Huntington’s studies, handing Ionis more bad news
July 10, 2026
 · 
2 min read
 · 
Tristan Manalac
Horizontal photo collage picture of people arms in gloves hold work instrument equipment hammer brush nail gun isolated on blue background.
Artificial intelligence
Biopharma R&D needs ‘structural redesign’ to maximize AI impact: report
July 9, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Stagflation, economic slow down or recession while inflation high up, GDP growth decrease causing by unemployment concept, fearful businessman riding fall down economic graph with inflation high up.
Cardiovascular disease
AstraZeneca, Ionis slip as ATTR-CM drug fails Phase 3
July 9, 2026
 · 
3 min read
 · 
Tristan Manalac
Podcast
Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil
July 8, 2026
 · 
1 min read
 · 
Jef Akst